Market Overview - As of October 29, the Shanghai Composite Index closed at 4016.33 points, up 28.11 points, with a gain of 0.70% [1] - The Shenzhen Component Index closed at 13691.38 points, up 261.28 points, with a gain of 1.95% [1] - The ChiNext Index closed at 3324.27 points, up 94.70 points, with a gain of 2.93% [1] High Turnover Stocks - A total of 84 A-shares had a turnover rate exceeding 20% on this day [1] - Notable stocks with high turnover rates include: - 泰凯英 (Tykang Technology) with a turnover rate of 69.82% and a closing price of 22.29 CNY, up 3.00% [1] - C超颖 (C Chaoying) with a turnover rate of 64.48% and a closing price of 86.75 CNY, up 12.08% [1] - 北方长龙 (Beifang Changlong) with a turnover rate of 51.81% and a closing price of 162.58 CNY, down 3.40% [1] - C禾元-U (C Heyuan) with a turnover rate of 50.96% and a closing price of 113.22 CNY, up 24.28% [1] Additional High Turnover Stocks - Other notable stocks with significant turnover rates include: - C必贝特-U (C Bibete) with a turnover rate of 49.99% and a closing price of 31.86 CNY, up 2.74% [1] - 威士顿 (Winston) with a turnover rate of 48.37% and a closing price of 61.52 CNY, up 19.99% [1] - 云汉芯城 (Yunhan Xincheng) with a turnover rate of 47.58% and a closing price of 236.20 CNY, up 6.16% [1] - 海峡创新 (Haixia Innovation) with a turnover rate of 45.41% and a closing price of 9.28 CNY, up 0.98% [1]

Core Points - The stock of Jianfa Zhixin experienced a decline of 11.66% today, with a turnover rate of 48.21% and a trading volume of 886 million yuan, indicating significant market activity [2] - Institutional investors net sold 40.27 million yuan, while brokerage seats collectively net sold 4.08 million yuan [2] - The stock has been listed on the Dragon and Tiger list 8 times in the past six months, with an average price drop of 0.06% the day after being listed and an average increase of 3.73% over the following five days [3] Trading Activity - The top five trading departments accounted for a total transaction amount of 148 million yuan, with a buying amount of 51.61 million yuan and a selling amount of 95.97 million yuan, resulting in a net sell of 44.36 million yuan [2] - Among the trading departments listed today, four institutional specialized seats were involved, with total buying amounts of 42.15 million yuan and selling amounts of 82.42 million yuan, leading to a net sell of 40.27 million yuan [2] Fund Flow - The stock saw a net outflow of 46.41 million yuan in main funds today, with a significant outflow of 18.12 million yuan from large orders and 28.29 million yuan from major funds [3] - Over the past five days, the main funds have seen a net inflow of 2.47 million yuan [3]

Group 1 - The core viewpoint of the article highlights the financial performance of Jianfa Zhixin for the third quarter of 2023, showing significant growth in revenue and net profit [1] - For the first three quarters of 2025, the company reported revenue of approximately 14.861 billion yuan, an increase of 10.18% year-on-year [1] - The net profit attributable to shareholders was about 230 million yuan, reflecting a year-on-year increase of 45.01% [1] - The basic earnings per share reached 0.64 yuan, which is a 45.45% increase compared to the previous year [1] Group 2 - As of the report date, Jianfa Zhixin's market capitalization stands at 16.6 billion yuan [2]

Group 1 - The core point of the article is that Jianfa Zhixin announced the results of its board meeting and provided details on its revenue composition for the first half of 2025, highlighting its market position and financial performance [1] Group 2 - Jianfa Zhixin's third board meeting was held on October 24, 2025, in Xiamen, where various proposals, including the revision of company policies, were discussed [1] - For the first half of 2025, the revenue composition of Jianfa Zhixin was as follows: vascular interventional devices accounted for 54.88%, surgical instruments for 18.91%, in vitro diagnostic reagents (IVD) for 14.36%, medical equipment for 5.77%, and other medical devices for 4.69% [1] - As of the report date, Jianfa Zhixin's market capitalization was 16.6 billion yuan [1]

证券代码：301584 证券简称：建发致新 公告编号：2025-005 上海建发致新医疗科技集团股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东大会 2、股东会的召集人：董事会 经上海建发致新医疗科技集团股份有限公司（以下简称"公司"）第三届董事 会第十次会议审议通过，决定召开公司2025年第二次临时股东大会。 3、会议召开的合法、合规性：本次会议的召集、召开符合《中华人民共和国 公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第2号—创业板上市公司规范运作》等法律、行政法规、部门规章、规 范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025年11月12日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年11月12日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为2025年 ...

证券代码：301584 证券简称：建发致新 公告编号：2025-004 二、监事会会议审议情况 1、审议通过《公司2025年第三季度报告》 上海建发致新医疗科技集团股份有限公司 关于第三届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海建发致新医疗科技集团股份有限公司（以下简称"公司"）第三届监事会 第九次会议通知于2025年10月13日以通讯方式送达，会议于2025年10月24日以通讯 方式召开。本次会议由李玉鹏先生主持，应出席监事3人，实际出席监事3人。本次 会议的通知、召开及审议程序符合有关法律法规和《公司章程》的规定，所作决议 合法有效。本次会议经逐项表决通过以下事项： 经审核，监事会认为董事会编制和审议《公司2025年第三季度报告》的程序符 合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司于同日披露于指定信息披露媒体及巨潮资讯网的《公司2025 年第三季度报告》（公告编号：2025-006）。 表决 ...

证券代码：301584 证券简称：建发致新 公告编号：2025-003 上海建发致新医疗科技集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海建发致新医疗科技集团股份有限公司（以下简称"公司"或"建发致新"） 第三届董事会第十次会议通知于2025年10月13日以通讯方式送达，会议于2025年10 月24日在厦门市思明区环岛东路1699号厦门建发国际大厦44楼3号会议室以现场结 合通讯的方式召开。本次会议由董事长余峰先生主持，应出席董事9人，实际出席 董事9人，其中王文怀先生、商沛先生、叶佳昌先生以通讯方式出席。本次会议的 通知、召开及审议程序符合有关法律法规和《公司章程》的规定，所作决议合法有 效。本次会议经逐项表决通过以下事项： 二、董事会会议审议情况 关于第三届董事会第十次会议决议公告 1、审议通过《公司2025年第三季度报告》 具体内容详见公司于同日披露于指定信息披露媒体及巨潮资讯网的《公司2025 年第三季度报告》（公告编号：2025-006）。 本议案已经公司第三届董事会审计委员会第五次会议审议通过。 表决 ...

中信证券股份有限公司 关于上海建发致新医疗科技集团股份有限公司 调整募投项目拟投入募集资金金额的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为上海 建发致新医疗科技集团股份有限公司（以下简称"建发致新"或"公司"）首次 公开发行股票和持续督导工作的保荐机构，根据《中华人民共和国公司法》《中 华人民共和国证券法》《证券发行上市保荐业务管理办法》《深圳证券交易所创业 板股票上市规则》等相关规定，对公司本次拟调整募集资金投资项目拟投入募集 资金金额事项进行了核查，具体情况如下： 一、募集资金的基本情况 根据中国证券监督管理委员会出具的《关于同意上海建发致新医疗科技集团 股份有限公司首次公开发行股票注册的批复》（证监许可〔2025〕1337 号），公 司获准首次向社会公众公开发行人民币普通股（A 股）股票（以下简称"本次发 行"）63,193,277 股，发行价格为人民币 7.05 元/股，募集资金总额为人民币 44,551.26 万元，扣除各项发行费用后募集资金净额为人民币 36,333.45 万元。上 述募集资金已于 2025 年 9 月 22 日划至公司指定账户，容诚会计师事务所（特殊 ...

中信证券股份有限公司 关于上海建发致新医疗科技集团股份有限公司 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为上海 建发致新医疗科技集团股份有限公司（以下简称"建发致新"或"公司"）首次 公开发行股票和持续督导工作的保荐机构，根据《中华人民共和国公司法》《中 华人民共和国证券法》《证券发行上市保荐业务管理办法》《深圳证券交易所创业 板股票上市规则》等相关规定，对公司本次拟使用部分暂时闲置募集资金进行现 金管理事项进行了核查，具体情况如下： 一、募集资金的基本情况 根据中国证券监督管理委员会出具的《关于同意上海建发致新医疗科技集团 股份有限公司首次公开发行股票注册的批复》（证监许可〔2025〕1337 号），公 司获准首次向社会公众公开发行人民币普通股（A 股）股票（以下简称"本次发 行"）63,193,277 股，发行价格为人民币 7.05 元/股，募集资金总额为人民币 44,551.26 万元，扣除各项发行费用后募集资金净额为人民币 36,333.45 万元。上 述募集资金已于 2025 年 9 月 22 日划至公司指定账户，容诚会计师事务所（特殊 普通合伙）对募集资金到位情况进行审验，并出 ...

Core Viewpoint - The company announced plans to utilize part of its idle raised funds for cash management, focusing on low-risk investment products to ensure safety and liquidity [1] Group 1: Company Actions - The company will hold the third board meeting and the ninth supervisory board meeting on October 24, 2025, to review the cash management proposal [1] - The company plans to use up to 180 million yuan of temporarily idle raised funds for cash management [1] - The investment will be in low-risk products such as structured deposits, time deposits, notice deposits, and large certificates of deposit [1] Group 2: Investment Strategy - The usage period for the funds will be effective for 12 months from the date of board approval [1] - The funds can be rolled over within the approved limit [1] - The company assures that this action will not affect the progress of the investment projects funded by the raised capital or its normal production and operations [1] Group 3: Market Considerations - The company will adjust its investment approach based on economic conditions and changes in the financial market [1] - There is a note of uncertainty regarding the actual returns from short-term investments [1]